Strategic objective and goals

Founded on Zealand Pharma’s core competencies in the discovery and development of innovative peptide drugs, we are committed to building a durable healthcare business providing new and better treatment options for patients with serious diseases.

To pursue this fundamental objective, we will continue to mature and expand our drug discovery and development activities and grow our portfolio of products in a disciplined way. We will maintain our strong focus on partnering – from innovation and technology enhancing alliances to product license agreements – striving to achieve optimal value growth in our business and to ensure an attractive return to our shareholders.

The following key strategic goals have been defined to guide our activities for the coming two to three years:

- Become a durably profitable company following the launch of lixisenatide – Lyxumia® by our partner Sanofi, retaining a disciplined approach to investments and spending
- Leverage our peptide discovery and development competences via R&D alliances with industrial and academic partners to sustain the inflow of novel drug candidates into the pipeline
- Maintain a global leading position in peptide drug design, optimization and development through investments in technology
- Use our leading position within peptide based drug innovation and development to attract new license and cost sharing agreements with commercial partners to advance and grow the pipeline:

to mitigate clinical development risk; and
to commercialize Zealand Pharma drugs and
ensure a growing revenue stream